Please assess the completion status of the following clinical trial:

Trial Title: A Study Comparing Daratumumab, Lenalidomide, and Dexamethasone With Lenalidomide and Dexamethasone in Relapsed or Refractory Multiple Myeloma

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE3
- Number of Arms: 2.0

Eligibility Criteria:
Inclusion Criteria:~* Must have documented multiple myeloma and measurable disease~* Must have received at least 1 prior line of therapy for multiple myeloma and achieved a response (partial response or better) to at least one prior regimen~* Must have documented evidence of progressive disease as defined by the International Myeloma Working Group criteria on or after their last regimen~* Must have an Eastern Cooperative Oncology Group Performance Status score of 0, 1, or 2~* If a participant has received subsequent anticancer therapy (salvage therapy), the participant must have a wash-out period defined as 2 weeks or 5 pharmacokinetic half-lives of the treatment, whichever is longer, before the planned start date of daratumumab monotherapy. The only exception is the emergency use of a short course of corticosteroids (equivalent of dexamethasone 40 milligram per day for a maximum of 4 days) before Daratumumab monotherapy~Exclusion Criteria:~* Has received any of the following therapies: daratumumab or other anti-CD38 therapies~* Has received anti-myeloma treatment within 2 weeks or 5 pharmacokinetic half-lives of the treatment~* Disease shows evidence of refractoriness or intolerance to lenalidomide or if previously treated with a lenalidomide-containing regimen the participant is excluded if he or she discontinued due to any adverse event related to prior lenalidomide treatment~* Has received autologous stem cell transplantation within 12 weeks before the date of randomization, or previously received an allogenic stem cell transplant (regardless of timing), or planning to undergo a stem cell transplant prior to progression of disease~* History of malignancy (other than multiple myeloma) within 5 years before the first dose of daratumumab monotherapy (exceptions are squamous and basal cell carcinomas of the skin and carcinoma in situ of the cervix, or breast, or other non-invasive lesion, that in the opinion of the investigator, with concurrence with the sponsor's medical monitor, is considered cured with minimal risk of recurrence within 5 years)

- Gender: ALL
- Minimum Age: 18 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Daratumumab + lenalidomide + dexamethasone (Type: EXPERIMENTAL): During each 28-day treatment cycle, participants will receive daratumumab, lenalidomide, and dexamethasone.
- Lenalidomide + dexamethasone (Type: ACTIVE_COMPARATOR): During each 28-day treatment cycle, participants will receive lenalidomide and dexamethasone.

Based on this trial design, predict the completion outcome and termination type (if applicable).